Download PDF
Klin Monbl Augenheilkd 2003; 220(6): 384-390
DOI: 10.1055/s-2003-40272
Übersicht
© Georg Thieme Verlag Stuttgart · New York

Therapie intraokulärer, ödematöser, proliferativer und neovaskulärer Erkrankungen durch intravitreales Triamcinolon-Acetonid

Treatment of Oedematous, Proliferative and Neovascular Diseases by Intravitreal Triamcinolone AcetonideJost  B.  Jonas1 , Ingrid  Kreissig1 , Robert  F.  Degenring1
  • 1Universitäts-Augenklinik, Fakultät für Klinische Medizin Mannheim der Ruprecht-Karls-Universität Heidelberg
Herrn Prof. Dr. med. Robert Machemer, der während zweier Forschungsaufenthalte als Alexander-von-Humboldt-Preisträger mich von der intravitrealen Triamcinolontherapie überzeugte, danke ich von ganzem Herzen
Further Information

Publication History

Eingegangen: 26. März 2003

Angenommen: 13. Mai 2003

Publication Date:
27 June 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Hintergrund: Rezente Studien deuten an, dass die intravitreale Injektion von kristallinem Triamcinolon-Acetonid möglicherweise eine therapeutische Zusatzoption zur Behandlung verschiedener intraokulärer, neovaskulärer, ödematöser und proliferativer Erkrankungen darstellt. Methode und Ergebnisse: Die relativ besten Therapieergebnisse sind wahrscheinlich bei intraretinalen ödematösen Erkrankungen zu erreichen, wie z. B. beim diffusen diabetischen Makulaödem und bei zystoiden Makulaödemen durch retinale Venenverschlüsse und Uveitis. Intravitreales Triamcinolon ist eventuell hilfreich zur angiostatischen Therapie bei Rubeosis iridis und proliferierenden ischämischen Retinopathien. Möglicherweise hat intravitreales Triamcinolon einen gewissen Einsatz bei der exsudativen altersassoziierten Makuladegeneration. Bei chronischer, therapieresistenter, okulärer Hypotonie am Übergang zur Phthisis bulbi kann manchmal durch eine intravitreale Injektion von Triamcinolon eine Steigerung des Augeninnendrucks und Stabilisierung erreicht werden. Die Rolle von intravitrealem Triamcinolon zur unterstützenden Therapie einer proliferativen Vitreoretinopathie ist unklar. Komplikationen der intravitrealen Triamcinoloninjektion sind eine okuläre Hypertension in ca. 50 % der injizierten Augen (bei einer Injektionsdosis von 25 mg Triamcinolon-Acetonid), was bei 1 % der injizierten Augen eine filtrierende Operation erfordert; ein kataraktogener Effekt und die postoperative infektiöse Endophthalmitis. Langzeitstudien von mehr als 3 Jahren Nachbeobachtungszeit fehlen, so dass über mögliche Spätkomplikationen keine wesentlichen Informationen vorliegen. Die Injektion kann mit einer Kataraktoperation kombiniert werden. Kataraktoperationen Monate nach der Injektion haben keine wesentlich erhöhte Komplikationsrate. Erfolgt auf eine erste intravitreale Injektion ein Visusanstieg, kann die Injektion wiederholt werden. Die Dauer der Wirkung einer intravitrealen Triamcinoloninjektion liegt wahrscheinlich zwischen 2 und 9 Monaten. Triamcinolon wurde bis zu 9 Monate nach einer Injektion von 25 mg im Kammerwasser nachgewiesen. Schlussfolgerungen: Die intravitreale Triamcinolontherapie ist möglicherweise eine zusätzliche Möglichkeit, um intraokuläre, ödematöse, neovaskuläre und proliferative Erkrankungen zu therapieren.

Abstract

Background: Recent studies have suggested that intravitreal triamcinolone acetonide may be a therapeutical possibility for treating of various intraocular neovascular, oedematous and proliferative diseases. Methods and results: Gain in visual acuity was relatively highest for eyes with intraretinal oedematous diseases such as diffuse diabetic macular oedema and various types of cystoid macular oedema due to reasons such as retinal venous occlusions and uveitis. Intravitreal triamcinolone may be useful as angiostatic therapy in eyes with iris neovascularisation and proliferative ischaemic retinopathies. Possibly, intravitreal triamcinolone may be helpful for exudative age-related macular degeneration. In eyes with chronic therapy resistant ocular hypotony, intravitreal triamcinolone can induce an increase in intraocular pressure. The role of intravitreal triamcinolone as adjunctive treatment of proliferative vitreoretinopathy has not been determined so far. Complications of intravitreal triamcinolone include secondary ocular hypertension in about 50 % of the eyes injected, with one per cent of the eyes necessitating antiglaucomatous filtrating surgery; a cataractogenic effect; and postoperative infectious endophthalmitis. Long-term studies of more than 3 years follow-up have been missing so far, so that there is no reliable information on long-term complications. The injection can be combined with cataract surgery. Cataract surgery performed some months after the injection did not show a markedly elevated rate of complications. If vision increases after the intravitreal triamcinolone injection, the injection can be repeated. The duration of the effect of a single intravitreal injection of triamcinolone ranges between 2 and 9 months. Triamcinolone acetonide was detected in the aqueous humour nine months after an intravitreal injection of 25 mg. Conclusions: Intravitreal triamcinolone acetonide may offer a possibility for adjunctive treatment of intraocular oedematous, neovascular and proliferative diseases.

Schlüsselwörter

Altersassoziierte Makuladegeneration - Antiangiogenese - diabetisches Makulaödem - Rubeosis iridis - Triamcinolon-Acetonid

Key words

Age-related macular degeneration - anti-angiogenesis - diabetic macular oedema - iris neovascularisation - triamcinolone acetonide

Literatur

  • 1 Antcliff R J, Spalton D J, Stanford M R, Graham E M, ffytche T J, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study.  Ophthalmology. 2001;  108 765-772
    CrossrefPubMedGoogle Scholar
  • 2 Antoszyk A N, Gottlieb J L, Machemer R, Hatchell D L. The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization.  Graefes Arch Clin Exp Ophthalmol. 1993;  231 34-40
    CrossrefPubMedGoogle Scholar
  • 3 Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A. Intravitreal triamcinolone for refractory pseudophakic macular edema.  Am J Ophthalmol. 2003;  135 246-249
    CrossrefPubMedGoogle Scholar
  • 4 Benitez Del Castillo Sanchez J M, Garcia Sanchez J. Intravitreal injection of triamcinolone acetonide in non infectious uveitis.  Arch Soc Esp Oftalmol. 2001;  76 661-664
    PubMedGoogle Scholar
  • 5 Benz M S, Murray T G, Dubovy S R, Katz R S, Eifrig C W. Endophthalmitis caused by Mycobacterium chelonae abscessus after intravitreal injection of triamcinolone.  Arch Ophthalmol. 2003;  121 271-273
    PubMedGoogle Scholar
  • 6 Berger A S, Cheng C K, Pearson P A, Ashton P, Crooks P A, Cynkowski T. et al . Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy.  Invest Ophthalmol Vis Sci. 1996;  37 2318-2325
    PubMedGoogle Scholar
  • 7 Bui Quoc E, Bodaghi B, Adam R, Burtin T, Cassoux N, Dreifuss S, Fardeau C, Lehoang P. Intraocular pressure elevation after subtenon injection of triamcinolone acetonide during uveitis.  J Fr Ophtalmol. 2002;  25 1048-1056
    PubMedGoogle Scholar
  • 8 Bynoe L A, Weiss J N. Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults.  Am J Ophthalmol. 2003;  135 382-384
    CrossrefPubMedGoogle Scholar
  • 9 Challa J K, Gillies M C, Penfold P L, Gyory J F, Hunyor A B, Billson F A. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow-up.  Aust N Z J Ophthalmol. 1998;  26 277-281
    PubMedGoogle Scholar
  • 10 Chen E P, Steinhorst U H, Samsa G P, Saloupis P T, Hatchell D L. The effect of combined daunorubicin and triamcinolone acetonide treatment on a refined experimental model of proliferative vitreoretinopathy.  Invest Ophthalmol Vis Sci. 1992;  33 2160-2164
    PubMedGoogle Scholar
  • 11 Ciulla T A, Criswell M H, Danis R P, Hill T E. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model.  Arch Ophthalmol. 2001;  119 399-404
    PubMedGoogle Scholar
  • 12 Coats M L, Peyman G A. Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis.  Retina. 1992;  12 46-51
    PubMedGoogle Scholar
  • 13 Conway M D, Canakis C, Livir-Rallatos C, Peyman G A. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema.  J Cataract Refract Surg. 2003;  29 27-33
    CrossrefPubMedGoogle Scholar
  • 14 Danis R P, Bingaman D P, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide.  Ophthalmology. 1996;  103 2099-2104
    PubMedGoogle Scholar
  • 15 Danis R P, Ciulla T A, Pratt L M, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.  Retina. 2000;  20 244-250
    CrossrefPubMedGoogle Scholar
  • 16 Degenring R F, Jonas J B. Intravitreal injection of triamcinolone acetonide as treatment of chronic uveitis.  Br J Ophthalmol. 2003;  87 361
    CrossrefPubMedGoogle Scholar
  • 17 Degenring R F, Kamppeter B, Kreissig I, Jonas J B. Morphologic and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion. Acta Ophthalmol 2003; im Druck
    Google Scholar
  • 18 Ghopal L, Bhende M, Sharma T. Vitrectomy for accidental intraocular steroid injection.  Retina. 1995;  15 295-299
    PubMedGoogle Scholar
  • 19 Graham R O, Peyman G A. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis.  Arch Ophthalmol. 1974;  92 149-154
    PubMedGoogle Scholar
  • 20 Greenberg P B, Martidis A, Rogers A H, Duker J S, Reichel E. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion.  Br J Ophthalmol. 2002;  86 247-248
    CrossrefPubMedGoogle Scholar
  • 21 Hefferman J T, Futterman S, Kalina R E. Dexamethasone inhibition of experimental endothelial cell proliferation in retinal venules.  Invest Ophthalmol Vis Sci. 1978;  17 565-568
    PubMedGoogle Scholar
  • 22 Ip M S, Kumar K S. Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion.  Arch Ophthalmol. 2002;  120 1217-1219
    PubMedGoogle Scholar
  • 23 Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan S J. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate.  Arch Ophthalmol. 1985;  103 708-711
    PubMedGoogle Scholar
  • 24 Jaffe G J, Ben-nun J, Guo H, Dunn J P, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis.  Ophthalmology. 2000;  107 2024-2033
    CrossrefPubMedGoogle Scholar
  • 25 Jonas J B, Hayler J K, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy.  Br J Ophthalmol. 2000;  84 1064-1067
    CrossrefPubMedGoogle Scholar
  • 26 Jonas J B, Hayler J K, Söfker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.  Am J Ophthalmol. 2001;  131 468-471
    CrossrefPubMedGoogle Scholar
  • 27 Jonas J B, Hayler J K, Panda-Jonas S. Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony. Short Communication.  Graefe's Arch Clin Exp Ophthalmol. 2001;  239 464-465
    PubMedGoogle Scholar
  • 28 Jonas J B, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema.  Am J Ophthalmol. 2001;  132 425-427
    CrossrefPubMedGoogle Scholar
  • 29 Jonas J B, Hayler J K, Söfker A, Panda-Jonas S. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone.  J Glaucoma. 2001;  10 284-287
    PubMedGoogle Scholar
  • 30 Jonas J B, Hayler J K, Panda-Jonas S. Intravitreal injection of crystalline cortisone as treatment of pre-phthisical ocular hypotony.  Graefe's Arch Clin Exp Ophthalmol. 2001;  239 464-465
    PubMedGoogle Scholar
  • 31 Jonas J B, Degenring R F. Intravitreale Injektion von kristallinem Triamcinolon Acetonid als Therapie des diffusen diabetischen Makulaödems.  Klin Monatsbl Augenheilkd. 2002;  219 429-432
    Article in Thieme ConnectPubMedGoogle Scholar
  • 32 Jonas J B. Concentration of intravitreally applicated triamcinolone acetonide in aqueous humour.  Brief Report Br J Ophthalmol. 2002;  86 1066
    PubMedGoogle Scholar
  • 33 Jonas J B, Kreissig I, Degenring R F. Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion.  Graefe's Arch Clin Exp Ophthalmol. 2002;  240 782-783
    PubMedGoogle Scholar
  • 34 Jonas J B, Kreissig I, Degenring R F. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Brief Report.  Graefe's Arch Clin Exp Ophthalmol. 2002;  240 872-873
    PubMedGoogle Scholar
  • 35 Jonas J B. Concentration of intravitreally injected triamcinolone acetonide in intraocular silicone oil.  Br J Ophthalmol. 2002;  86 1450-1451
    CrossrefPubMedGoogle Scholar
  • 36 Jonas J B, Söfker A. Intravitreal triamcinolone acetonide for cataract surgery with iris neovascularisation.  J Cataract Refr Surg. 2002;  28 2040-2041
    PubMedGoogle Scholar
  • 37 Jonas J B, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide.  Br J Ophthalmol. 2003;  87 24-27
    CrossrefPubMedGoogle Scholar
  • 38 Jonas J B, Kreissig I, Söfker A, Degenring R F. Intravitreal injection of triamcinolone acetonide for diabetic macular edema.  Arch Ophthalmol. 2003;  121 57-61
    PubMedGoogle Scholar
  • 39 Jonas J B, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration.  Br J Ophthalmol. 2003;  87 462-468
    CrossrefPubMedGoogle Scholar
  • 40 Jonas J B, Kreissig I, Degenring R F. Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide.  Arch Ophthalmol. 2003;  121 729-730
    CrossrefPubMedGoogle Scholar
  • 41 Jonas J B, Kreissig I, Degenring R F. Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Arch Ophthalmol 2003; im Druck
    Google Scholar
  • 42 Jonas J B, Söfker A, Degenring R F. Intravitreal triamcinolone acetonide as additional tool in pars plana vitrectomy for proliferate diabetic retinopathy. Eur J Ophthalmol 2003; im Druck
    Google Scholar
  • 43 Jonas J B, Kreissig I, Degenring R F. Repeated intravitreal triamcinolone injections as treatment of ischemic ophthalmopathy. Eur J Ophthalmol 2003; im Druck
    Google Scholar
  • 44 Jonas J B, Söfker A, Hayler J, Degenring R F. Intravitreal crystalline triamcinolone acetonide as additional tool in pars plana vitrectomy for complicated proliferative vitreoretinopathy?. Acta Ophthalmol zur Publikation angenommen
    Google Scholar
  • 45 Machemer R, Sugita G, Tano Y. Treatment of intraocular proliferations with intravitreal steroids.  Trans Am Ophthalmol Soc. 1979;  77 171-180
    PubMedGoogle Scholar
  • 46 Machemer R. Five cases in which a depot steroid (hydrocortisone acetate and methylprednisolone acetate) was injected into the eye.  Retina. 1996;  16 166-167
    PubMedGoogle Scholar
  • 47 Martidis A, Duker J S, Puliafito C A. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy.  Arch Ophthalmol. 2001;  119 1380-1383
    PubMedGoogle Scholar
  • 48 Martidis A, Duker J S, Greenberg P B, Rogers A H, Puliafitto C A, Reichel E, Baumal C. Intravitreal triamcinolone for refractory diabetic macular edema.  Ophthalmology. 2002;  109 920-927
    CrossrefPubMedGoogle Scholar
  • 49 McCuen B W, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide.  Am J Ophthalmol. 1981;  91 785-788
    PubMedGoogle Scholar
  • 50 Gillies M C, Luo W, Chua W, Cherepanoff S, Billson F A, Mitchell P, Simpson J. The efficacy of a single intravitreal injection of triamcinolone for neovascular age-related macular degeneration. One year results of a randomised clinical trial: IVTAS.  Invest Ophthalmol Vis Sci. 2001;  42, Suppl ARVO Abstract # 2808
    PubMedGoogle Scholar
  • 51 Modarres M, Parvaresh M M, Peyman G A. Accidental subretinal injection of triamcinolone acetonide.  Ophthalmic Surg Lasers. 1998;  29 935-938
    PubMedGoogle Scholar
  • 52 Moshfeghi D M, Lowder C Y, Roth D B, Kaiser P K. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection.  Am J Ophthalmol. 2002;  134 132-134
    CrossrefPubMedGoogle Scholar
  • 53 Penfold P L, Gyory J F, Hunyor A B, Billson F A. Exudative macular degeneration and intravitreal triamcinolone. A pilot study.  Aust NZ J Ophthalmol. 1995;  23 293-298
    PubMedGoogle Scholar
  • 54 Penfold P L, Wong J G, Gyory J, Billson F A. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration.  Clin Experiment Ophthalmol. 2001;  29 188-192
    CrossrefPubMedGoogle Scholar
  • 55 Penfold P L, Wen L, Madigan M C, King N J, Provis J M. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells.  Invest Ophthalmol Vis Sci. 2002;  43 3125-3130
    PubMedGoogle Scholar
  • 56 Penfold P L. Intravitreal triamcinolone in recurrence of choroidal neovascularisation.  Br J Ophthalmol. 2002;  86 600-601
    CrossrefPubMedGoogle Scholar
  • 57 Penn J S, Rajaratnam V S, Collier R J, Clark A F. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity.  Invest Ophthalmol Vis Sci. 2001;  42 283-290
    PubMedGoogle Scholar
  • 58 Peyman G A, Cheema R, Conway M D, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy.  Retina. 2000;  20 554-555
    CrossrefPubMedGoogle Scholar
  • 59 Ranson N T, Danis R P, Ciulla T A, Pratt L. Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration.  Br J Ophthalmol. 2002;  86 527-529
    CrossrefPubMedGoogle Scholar
  • 60 Reinhard T, Sundmacher R. Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty. A pilot study. Transplant International.  I Transpl Int. 2002;  15 81-88
    PubMedGoogle Scholar
  • 61 Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno A, Itaya K, Ishibashi T. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown.  Graefes Arch Clin Exp Ophthalmol. 2002;  240 423-429
    CrossrefPubMedGoogle Scholar
  • 62 Schindler R H, Chandler D B, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide.  Am J Ophthalmol. 1982;  93 415-417
    PubMedGoogle Scholar
  • 63 Scholes G N, O'Brien W J, Abrams G W, Kubicek M F. Clearance of triamcinolone from vitreous.  Arch Ophthalmol. 1985;  103 1567-1569
    PubMedGoogle Scholar
  • 64 Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.  Am J Ophthalmol. 1980;  90 810-816
    PubMedGoogle Scholar
  • 65 Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferation with intravitreal corticosteroid.  Am J Ophthalmol. 1980;  89 131-136
    PubMedGoogle Scholar
  • 66 Wang Y S, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells.  Graefe's Arch Clin Exp Ophthalmol. 2002;  240 42-48
    PubMedGoogle Scholar
  • 67 Wilson C A, Berkowitz B A, Sato Y, Ando N, Handa J T, de Juan E. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation.  Arch Ophthalmol. 1992;  110 1155-1159
    CrossrefPubMedGoogle Scholar
  • 68 Wingate R J, Beaumont P E. Intravitreal triamcinolone and elevated intraocular pressure.  Aust N Z J Ophthalmol. 1999;  27 431-432
    CrossrefPubMedGoogle Scholar
  • 69 Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis.  Clin Experiment Ophthalmol. 2001;  29 2-6
    CrossrefPubMedGoogle Scholar

Prof. Dr. Jost B. Jonas

Universitäts-Augenklinik

Theodor-Kutzer-Ufer 1 - 3

68167 Mannheim

Phone: 0621/383-2242

Fax: 0621/383-3803

Email: Jost.Jonas@augen.ma.uni-heidelberg.de